Blog Archives

FDA approves Siltuximab [Sylvant] for rare Castleman’s disease

April 23, 2014 – The U.S. Food and Drug Administration today approved Sylvant (siltuximab) to treat patients with multicentric Castleman’s disease (MCD), a rare disorder similar to lymphoma (cancer of the lymph nodes).

MCD causes an abnormal overgrowth of immune cells in lymph nodes and related tissues in the body.

Read more ›

Tags: , , , , , , ,

Boxed Warning Updated: TNF Blockers and Cancer Risks in Children

November 3, 2009 – As we learn from it’s todays announcement, FDA is requiring stronger warnings about an increased risk of lymphoma and other cancers in children and adolescents who are treated with drugs that block tumor necrosis factor. TNF blockers include Infliximab [Remicade], Etanercept [Enbrel], Adalizumab [Humira], Certolizumab [Cimzia],

Read more ›

Tags: , , , , , , , , ,

thasso: donate

We need your help. Please support the development of thasso through donations. Thank you.    Nous avons besoin de votre aide. S'il vous plaît, vous pouvez soutenir le développement de thasso grâce à des dons. Merci.    Wir brauchen Ihre Hilfe. Bitte unterstützen Sie die Entwicklung von thasso durch Spenden. Vielen Dank.    Abbiamo bisogno del tuo aiuto. Si prega di sostenere lo sviluppo di thasso attraverso donazioni. Grazie.    Nós precisamos da sua ajuda. Por favor, apoie o desenvolvimento de thasso através de doações. Obrigada.     Necesitamos tu ayuda. Por favor apoye el desarrollo de thasso con donaciones. Muchas gracias.

thasso: conditions

thasso: newest tweets

Recent Comments

Top
Skip to toolbar